Latest Intelligence on Biotechnology in Ireland

Published within

« | 1 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Vernalis: Frovelan concerns a headache for shareholders

Published By Datamonitor
20 Sep 2001
CommentWire
CommentWire

Novuspharma: lending a hand to Micromet

Novuspharma has agreed to co-develop Micromet's MT201, the only fully human antibody in development that targets the Ep-CAM molecule. The companies plan to begin phase II trials for the drug, across a wide range of cancers. Novuspharma's expertise and experience in oncology will aid MT201's development, but the companies will also need an experienced marketing partner.

Published By Datamonitor
02 Sep 2002
CommentWire
CommentWire

Elan: to Genomics and Beyond

Published By Datamonitor
17 May 2001
CommentWire
CommentWire

Elan/Biogen Idec: Tysabri sees further safety success

Elan and Biogen Idec can breathe a little easier having announced the second round of positive results about the safety of their multiple sclerosis drug Tysabri. These results, which come less than a year after the voluntary withdrawal of the drug from the US market following the death of two patients from a fatal brain disorder, suggest a promising future could still be possible for Tysabri.

Published By Datamonitor
18 Oct 2005

« | 1 | » »|

No help is available.